Sign In

Claus Andersson

General Partner, PhD, Life Science Venture Capital

Claus Andersson is a General Partner at Sunstone Life Science Ventures who recently joined the Board of Directors at Resalis Therapeutics.13 His appointment to the board came in conjunction with Sunstone Life Science Ventures leading a €10 million Series A financing round for Resalis Therapeutics.14

Professional Background

Claus Andersson has extensive experience in the biotech and life sciences sector. As a General Partner at Sunstone Life Science Ventures, he plays a key role in identifying and investing in promising life science companies.5 His expertise likely includes evaluating potential investments, providing strategic guidance, and supporting portfolio companies' growth.

Board Positions

In addition to his new role at Resalis Therapeutics, Claus Andersson serves on the Board of Directors for multiple biotech companies, including:

  • DiogenX
  • Rewind Therapeutics
  • Cardior Pharmaceuticals5

Involvement with Resalis Therapeutics

Claus Andersson's involvement with Resalis Therapeutics is significant for several reasons:

  1. Investment Leadership: He led Sunstone Life Science Ventures' participation in Resalis' €10 million Series A funding round.12

  2. Strategic Guidance: As a board member, he will likely provide valuable insights and guidance to help Resalis advance its lead program, RES-010, through clinical trials.1

  3. Industry Expertise: His experience in the life sciences sector could be instrumental in helping Resalis navigate the challenges of developing innovative therapies for obesity and metabolic disorders.3

Claus Andersson's addition to the Resalis board underscores Sunstone Life Science Ventures' confidence in the company's approach to treating obesity and its potential to make a significant impact in the field of metabolic disorders.1

Highlights

Oct 3 · linkedin

We want to quantify the benefits of investing in development of new therapies, and we think RALYS could be an effective way to go about it. Follow #sunstonelifescience if you want to know more about what development of novel medicines is contributing with.

One of our main goals at Sunstone Life Science Ventures is to develop new therapies that can improve the lives of patients To measure the impact of our innovation, we use a tool called RALYS, which stands for Risk Adjusted Life Years Saved. RALYS captures the value of a new therapy by estimating how many years of life it can save or extend for the patients who need it. By using RALYS, we can compare different therapies and prioritize the ones that have the most potential to make a difference. If you are interested in learning more about RALYS and how we use it to guide our development of novel medicines, follow us on #sunstonelifescience and stay tuned for more updates.

Mar 2 · linkedin

We have conducted an analysis on all pre-commercial listed biotech companies on the main stock exchanges. I think the article conveys a positive message and facts that should spur optimism... #sunstonelifescience

Related Questions

What is Claus Andersson's background in the biotech industry?
How did Claus Andersson get involved with Sunstone Life Science Ventures?
What other companies does Claus Andersson serve on the board of?
What is the significance of RES-010 in the treatment of obesity?
How does non-coding RNA-based therapy work in metabolic disorders?
Claus Andersson
Claus Andersson, photo 1
Claus Andersson, photo 2
Add to my network

Location

Copenhagen, Capital Region of Denmark, Denmark